GSK plc (GSK)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Vaccines/Respiratorysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-12. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 15/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength
- Is the Options Market Predicting a Spike in GSK Plc Stock?
- Viola Davis partners with GSK to educate adults 50 and older about their shingles risk
- Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies
- GSK retains ‘buy’ rating at Jefferies as B7H3 cancer programme seen as underappreciated
- Berenberg Turns Bullish on GSK as its $750 Million Deal Adds to Pipeline Momentum
- GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger?
- Bioscience Association Manitoba Welcomes New Board Members and Executive Members at Annual General Meeting
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial). — Eur J Cancer 2026 Oct 16 PMID 42748587
- International consensus on intestinal epithelial barrier assessment and therapeutic effects in inflammatory bowel diseases clinical trials. — Gut 2026 Jul 16 PMID 42463422
- Consensus Statement from the Society of Gynecologic Oncology of Canada on Folate Receptor α Testing in Ovarian Cancer. — Curr Oncol 2026 Jun 1 PMID 42346230
- Developing low-carbon salbutamol MDI: assessment of relative bioavailability and pharmacodynamic relative potency of salbutamol MDI with propellant HFA-152a. — BMJ Open Respir Res 2026 Jun 17 PMID 42309649
- Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules. — Clin Genitourin Cancer 2026 Aug PMID 42217273
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for GSK plc.
Full GSK Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.